Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Catherine Rose Scholz
Observed names:
C Scholz,
C. Scholz,
Catherine Scholz,
Scholz, Catherine
Observed institutions:
The University of Texas MD Anderson Cancer Center,
Genentech,
Regeneron (United States),
Kura Oncology (United States),
Medscape,
Takeda Oncology (United States)
show all 6
OpenAlex ID:
A5063754396
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
2011
·
Asit Parikh
, Timothy Leach
, et al.
·
Inflammatory Bowel Diseases
·
210
PDF
Tipifarnib in Head and Neck Squamous Cell Carcinoma WithHRASMutations
2021
·
Alan L. Ho
, Irene Brana
, et al.
·
Journal of Clinical Oncology
·
204
PDF
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
2021
·
David P. Steensma
, Martin Wermke
, et al.
·
Leukemia
·
189
PDF
A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas
2008
·
Lia Gore
, Mace L. Rothenberg
, et al.
·
Clinical Cancer Research
·
170
PDF
A phase I surrogate endpoint study of SU6668 in patients with solid tumors
2004
·
Henry Q. Xiong
, Roy Herbst
, et al.
·
Investigational New Drugs
·
84
Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
2013
·
Asit Parikh
, Irving Fox
, et al.
·
Inflammatory Bowel Diseases
·
80
Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
2021
·
Marta Rodríguez
, Ruth Alonso-Alonso
, et al.
·
Blood Advances
·
55
PDF
Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer
2020
·
Glenn J. Hanna
, Jeffrey P. Guenette
, et al.
·
Cancer
·
55
PDF
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
2020
·
Hye Won Lee
, Jason K. Sa
, et al.
·
Clinical Cancer Research
·
44
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers
2016
·
Maria Rosario
, Timothy Wyant
, et al.
·
Clinical Drug Investigation
·
44
Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
2010
·
S. F. Jones
, R. B. Cohen
, et al.
·
Journal of Clinical Oncology
·
27
Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
2020
·
Alan Loh Ho
, Glenn J. Hanna
, et al.
·
Journal of Clinical Oncology
·
20
Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
2021
·
Stephen R. D. Johnston
, Timothy J. Pluard
, et al.
·
Journal of Clinical Oncology
·
14
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma
2020
·
Ruth Alonso-Alonso
, Rufino Mondéjar
, et al.
·
Scientific Reports
·
11
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
2019
·
Thomas E. Witzig
, Lubomir Sokol
, et al.
·
Blood
·
11
Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
2019
·
Alan Ho
, Irene Brana
, et al.
·
Molecular Cancer Therapeutics
·
8
Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas
2018
·
A. Ho
, N. Chau
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
8
Abstract CT191: Mechanism of action of the farnesyltransferase inhibitor, tipifarnib, and its clinical applications
2019
·
Antonio Gualberto
, Catherine Scholz
, et al.
·
Cancer Research
·
6
An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.
2017
·
Alan Loh Ho
, Nicole Grace Chau
, et al.
·
Journal of Clinical Oncology
·
6
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T‐cell Lymphoma (aitl) and Cxcl12+ Peripheral T‐cell Lymphoma (ptcl): Preliminary Results From a Phase 2 Study
2019
·
T. Witzig
, L. Sokol
, et al.
·
Hematological Oncology
·
5
The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes
2017
·
Antonio Gualberto
, Catherine Scholz
, et al.
·
Blood
·
5
Preliminary Results From an Open‐label, Phase Ii Study of Tipifarnib in Relapsed or Refractory Peripheral T‐cell Lymphoma
2017
·
T. Witzig
, L. Sokol
, et al.
·
Hematological Oncology
·
5
PDF
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
2009
·
C. Scholz
, T. Wyant
, et al.
·
Journal of Crohn s and Colitis
·
4
Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
2018
·
Alan Ho
, Nicole Chau
, et al.
·
Molecular Cancer Therapeutics
·
3
Patient reported abdominal pain as a surrogate of the clinical benefit of tipifarnib in pancreatic cancer patients.
2019
·
Antonio Gualberto
, Catherine Rose Scholz
, et al.
·
Journal of Clinical Oncology
·
2
Show more works
View as search
Works count:
55
Citation count:
1,277
H-index:
13
I10-index:
15
Year
Topic
Type
